Women with familial risk for breast cancer have an increased frequency of aldehyde dehydrogenase expressing cells in breast ductules

BMC Clinical Pathology

Håkan Olsson²  Per Alm¹  Helena Jernström⁵  Bo Holmqvist⁴  Björn L Isfoss³ 

[1]Department of Pathology, Clinical Sciences Lund, Lund University, SE-221 85 Lund, Sweden

[2]Department of Cancer Epidemiology, Clinical Sciences Lund, Lund University, SE-221 85 Lund, Sweden

[3]Department of Pathology, Skane University Hospital, SE-221 85 Lund, Sweden

[4]ImaGene-iT AB, Medicon Village, SE-223 81 Lund, Sweden

[5]Department of Oncology, Clinical Sciences Lund, Lund University, SE-221 85 Lund, Sweden

关键词: Breast ductules;    Immunohistochemistry;    Histology;    BRCA2;    BRCA1;    Familial cancer;    Breast neoplasia;    Aldehyde dehydrogenase;    Stem cells;   

Others  :  1084774
DOI  :  10.1186/1472-6890-13-28

 received in 2013-04-22, accepted in 2013-10-30,  发布年份 2013

【 摘 要 】

Background

Knowledge is limited regarding the association between stem cells in histologically benign breast tissue and risk factors for breast cancer, and hence we addressed this issue in the present study. Recently, we assessed the histology of benign breast tissue from cancer and non-cancer patients for cells positive for the putative stem cell marker aldehyde dehydrogenase 1 A1 (ALDH), and the findings indicated an association between expression of ALDH and the hormonal factors menopause and hormone therapy. The current investigation examined possible associations between various known clinical and genetic risk factors for breast cancer and cellular expression of ALDH in ductules in benign human breast tissue.

Methods

The study included breast surgery patients that were BRCA1/2 mutation carriers without breast cancer (n = 23), had BRCA1/2 (n = 28) or sporadic (n = 21) breast cancer, or required non-cancer-related mammoplasty (n = 34). The distribution and frequency of ALDH-immunolabelled cells were correlated to patient subgroups with different risk factors, using mammoplasty patients as a control group. Statistical analyses comprised linear and logistic regression, Spearman’s rank test, Pearson’s test, and Fisher’s exact test. In two-tailed tests, p < 0.05 was considered significant.

Results

A strong association was found between family history of breast cancer and a high frequency of ALDH+ cells (p = 0.001) at all ductular levels in all groups, regardless of BRCA status, age, parity, or occurrence of cancer. In pre-menopausal non-BRCA cancer patients, the frequency of ALDH+ cells increased with age (p < 0.01) but decreased with increasing parity (p < 0.03). High frequencies of ALDH+ cells were found in the non-basal ductular levels in BRCA1 mutation carriers (p = 0.03), but in the basal ductular level in BRCA2 cancer patients (p = 0.02). Among post-menopausal patients, only on-going hormone replacement therapy was correlated with a high number of ALDH+ cells (p < 0.03).

Conclusion

In histologically normal breast tissue, we found a positive association between the frequency of ductular ALDH+ cells and several breast cancer risk factors, particularly family history of this disease, which supports previous evidence that ALDH plays a role in breast cancer.

【 授权许可】

   
2013 Isfoss et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

【 参考文献 】

• [1]Clarke MF, Dick JE, Dirks PB, Eaves CJ, Jamieson CH, Jones DL, Visvader J, Weissman IL, Wahl GM: Cancer stem cells—perspectives on current status and future directions: AACR workshop on cancer stem cells. Cancer Res 2006, 66:9339-9344.
• [2]Alvi AJ, Clayton H, Joshi C, Enver T, Ashworth A, Vivanco M, Dale TC, Smalley MJ: Functional and molecular characterisation of mammary side population cells. Breast Cancer Res 2003, 5:R1-R8.
• [3]Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF: Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci 2003, 100:3983-3988.
• [4]Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M, Jacquemier J, Viens P, Kleer CG, Liu S, Schott A, Hayes D, Birnbaum D, Wicha MS, Dontu G: ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 2007, 15:555-567.
• [5]Tanei T, Morimoto K, Shimazu K, Kim SJ, Tanji Y, Taguchi T, Tamaki Y, Noguchi S: Association of breast cancer stem cells identified by aldehyde dehydrogenase 1 expression with resistance to sequential paclitaxel and epirubicin-based chemotherapy for breast cancers. Clin Cancer Res 2009, 15:4234-4241.
• [6]Ma I, Allan AL: The role of human aldehyde dehydrogenase in normal and cancer stem cells. Stem Cell Rev 2011, 7:292-306.
• [7]Eirew P, Kannan N, Knapp DJ, Valliant F, Emerman JT, Lindeman GJ, Visvader JE, Eaves CJ: Aldehyde dehydrogenase activity is a biomarker of primitive normal human mammary luminal cells. Stem Cells 2012, 30:344-348.
• [8]Fackenthal JD, Olopade OI: Breast cancer risk associated with BRCA1 and BRCA2 in diverse populations. Nat Rev Cancer 2007, 7:937-948.
• [9]Beral V, Reeve G, Bull D, Green J, Million Women Study Collaborators: Breast cancer risk in relation to the interval between menopause and starting hormone therapy. J Natl Cancer Inst 2011, 103:296-305.
• [10]Sinn HP, Elsawaf Z, Helmchen B, Aulmann S: Early breast cancer precursor lesions: lessons learned from molecular and clinical studies. Breast Care 2010, 5:218-226.
• [11]Reya T, Morrison SJ, Clarke MF, Weissmann IL: Stem cells, cancer, and cancer stem cells. Nature 2001, 414:105-111.
• [12]Nalwoga H, Arnes JB, Wabinga H, Akslen LA: Expression of aldehyde dehydrogenase (ALDH1) is associated with basal-like markers and features of aggressive tumours in African breast cancer. Br J Cancer 2010, 102:369-375.
• [13]Kunju LP, Cookingham C, Toy KA, Chen W, Sabel MS, Kleer CG: EZH2 and ALDH-1 mark breast epithelium at risk for breast cancer developement. Mod Pathol 2011, 24:786-793.
• [14]Schwartz T, Stark A, Pang J, Awuah B, Kleer CG, Quayson S, Kingman S, Aitpillah F, Jiagge E, Oppong JK, Osei-Bonsu E, Martin I, Yan X, Toy K, Adjei E, Wicha M, Newman LA: Expression of aldehyde dehydrogenase 1 as a marker of mammary stem cells in benign and malignant breast lesions of Ghanaian women. Cancer 2013, 119:488-494.
• [15]Isfoss BL, Holmqvist B, Alm P, Olsson H: Distribution of aldehyde dehydrogenase 1-positive stem cells in benign mammary tissue from women with and without breast cancer. Histopathology 2012, 60:617-633.
• [16]Ashworth A, Weber BL, Domchek SM: Inherited genetic factors and breast cancer. In Diseases of the breast. Edited by Harris JR, Morrow M, Lippman ME, Osborne CK. Philadelphia: Wolters Kluwer; 2010:209-220.
• [17]Schonfeld SJ, Pfeiffer RM, Lacey JV, Berrington de Gonzalez A, Doody MM, Greenlee RT, Park Y, Schairer C, Schatzkin A, Sigurdson AJ, Hartge P, Visvanathan K: Hormone-related risk factors and postmenopausal breast cancer among nulliparous versus parous women: an aggregated study. Am J Epidemiol 2011, 173:509-517.
• [18]Collaborative Group on Hormonal Factors in Breast Cancer: Breast cancer and hormone replacement therapy. Collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer. Lancet 1997, 350:1047-1059.
• [19]Olsson HL, Ingvar C, Bladström A: Hormone replacement therapy containing progestins and given continuously increases breast carcinoma risk in Sweden. Cancer 2003, 97:1387-1392.
• [20]Beral V, Million Women Study Collaborators: Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003, 362:419-427.
• [21]Anderson GL, Judd HL, Kaunitz AM, Barad DH, Beresford SA, Pettinger M, Liu J, McNeeley SG, Lopez AM, Women’s Health Initiative Investigators: Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: the women’s health initiative randomized trial. JAMA 2003, 290:1739-1748.
• [22]Albanes D, Winick M: Are cell number and cell proliferation risk factors for cancer? J Natl Cancer Inst 1988, 80:772-774.
• [23]Olsson H: Risk for malignant tumors after oral contraceptive use: is it related to organ size while taking the pill? Med Oncol Tumor Pharmacother 1990, 7:61-64.